The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Diagnosing & Managing Pulmonary & Kidney Manifestations in Lupus

Diagnosing & Managing Pulmonary & Kidney Manifestations in Lupus

February 17, 2019 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

CHICAGO—In systemic lupus erythematosus (SLE), most types of severe pulmonary manifestations are relatively rare, but it’s crucial they be caught because of the potentially dire consequences, said Richard Silver, MD, professor in the Rheumatology Division at the Medical University of South Carolina, Charleston, at the 2018 ACR/ARHP Annual Meeting.

You Might Also Like
  • Lupus Patients Have More Lethal Form of Kidney Disease
  • Systemic Lupus Erythematosus Without Kidney Involvement: A Case Report
  • IgG4-Related Kidney Disease: Diagnostics, Manifestations & More
Explore This Issue
February 2019
Also By This Author
  • ACR/ARHP Annual Meeting 2012: Electronic Portals Appeal to Patients

Pulmonary Manifestations

Parenchymal disease—seen in the form of acute lupus pneumonitis, acute respiratory distress syndrome, diffuse alveolar hemorrhage and chronic interstitial pneumonitis—appears in less than 5% of lupus patients. Its mortality rate can run as high as 50%.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“When you see it, you’ve got to recognize it. You’ve got to know you’ve seen it because it can be catastrophic,” Dr. Silver said.

Acute lupus pneumonitis (ALP) usually presents with abrupt fever onset, cough, pleurisy and dyspnea, and is marked by evidence of lupus activity, such as double-stranded DNA antibodies, low C3 and C4, pleural effusions and alveolar infiltrates. The initial concern should be excluding infection, with immunosuppression treatment once infection is ruled out.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Diffuse alveolar hemorrhage (DAH), also rare but potentially fatal, can resemble ALP, but if hemoptysis is also present, consider DAH, Dr. Silver said. A falling hematocrit is a telltale sign of DAH, and rituximab has shown efficacy in its treatment.1

Risk factors for pulmonary arterial hyper­tension (PAH) in SLE include Raynaud’s phenomenon, anti-U1 RNP antibodies, anti-cardiolipin antibodies and anti-endothelial cell antibodies. High-risk patients can be screened with pulmonary function tests and echocardiogram, though the gold diagnostic standard is right heart catheterization.

A diagnosis occurs when a high pulmonary arterial pressure with a non-elevated pulmonary capillary wedge pressure and a pulmonary vascular resistance of greater than or equal to 3 Wood units are evident.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“You might have pulmonary hyper­tension on an echo or even on a right heart catheterization,” Dr. Silver said, “but if the [wedge pressure is elevated], it’s not PAH. It’s diastolic dysfunction or some other cardiac issue leading to pulmonary hypertension. Unless it’s PAH, you shouldn’t embark on PAH-specific therapy.”

More therapeutic options have emerged in recent years, he said.

“We now have a host of PAH-specific therapies,” Dr. Silver said. “Most people would either use monotherapy with an oral agent, or a dual combination oral therapy using both a PDE5 inhibitor and an endothelin receptor antagonist (ERA). This really requires the input of a PAH specialist. If patients are failing mono- or dual-combination therapy, that therapy needs to be escalated, and this usually requires a multidisciplinary approach.”

Colored computed tomography (CT) scans of axial sections through the chest of a 68-year-old patient with interstitial lung disease (diffuse parenchymal lung disease, DPLD). Parenchymal disease appears in less than 5% of lupus patients.

Colored computed tomography (CT) scans of axial sections through the chest of a 68-year-old patient with interstitial lung disease (diffuse parenchymal lung disease, DPLD). Parenchymal disease appears in less than 5% of lupus patients.
Zephyr / Science Source

Kidney Manifestations

Severe lupus manifestations in the kidney can prove challenging to manage, said Derek Fine, MD, a nephrologist and associate professor of medicine at Johns Hopkins, Baltimore. But he offered these suggestions on how to make the best of a challenging situation:

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, SLE (Lupus) Tagged With: 2018 ACR/ARHP Annual Meeting, acute lupus pneumonitis, belimumab, diffuse alveolar hemorrhage, parenchymal disease, pulmonary arterial hypertension, rituximabIssue: February 2019

You Might Also Like:
  • Lupus Patients Have More Lethal Form of Kidney Disease
  • Systemic Lupus Erythematosus Without Kidney Involvement: A Case Report
  • IgG4-Related Kidney Disease: Diagnostics, Manifestations & More
  • Low Blood Pressure Increases Risk of Death in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)